Mirum Pharmaceuticals (NASDAQ:MIRM) Coverage Initiated by Analysts at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM - Free Report) in a research report released on Wednesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $48.00 price target on the stock.

MIRM has been the topic of a number of other reports. HC Wainwright reaffirmed a buy rating and set a $58.00 target price on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 2nd. Cantor Fitzgerald reiterated an overweight rating and issued a $35.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. Raymond James cut their target price on Mirum Pharmaceuticals from $78.00 to $64.00 and set a strong-buy rating for the company in a research note on Tuesday, December 19th. JMP Securities lifted their target price on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an outperform rating in a research report on Thursday, March 14th. Finally, SVB Leerink lowered their price target on Mirum Pharmaceuticals from $44.00 to $43.00 and set an outperform rating for the company in a report on Monday, March 18th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Buy and a consensus price target of $51.70.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock traded down $0.16 on Wednesday, hitting $23.85. 327,435 shares of the company were exchanged, compared to its average volume of 572,455. Mirum Pharmaceuticals has a 1-year low of $23.76 and a 1-year high of $35.56. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -6.07 and a beta of 1.14. The company has a quick ratio of 4.19, a current ratio of 4.45 and a debt-to-equity ratio of 1.23. The company has a 50-day moving average price of $27.10 and a 200 day moving average price of $28.59.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. The company had revenue of $69.55 million during the quarter, compared to analyst estimates of $66.73 million. As a group, sell-side analysts predict that Mirum Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the business's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the completion of the transaction, the chief operating officer now owns 29,013 shares in the company, valued at $748,535.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, COO Peter Radovich sold 4,303 shares of the firm's stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the sale, the chief operating officer now owns 29,013 shares of the company's stock, valued at $748,535.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Eric Bjerkholt purchased 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average price of $25.80 per share, with a total value of $51,600.00. Following the purchase, the chief financial officer now directly owns 12,000 shares of the company's stock, valued at $309,600. The disclosure for this purchase can be found here. 24.06% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Polar Capital Holdings Plc raised its holdings in Mirum Pharmaceuticals by 27.0% during the third quarter. Polar Capital Holdings Plc now owns 1,175,000 shares of the company's stock worth $37,130,000 after purchasing an additional 250,000 shares in the last quarter. Raymond James & Associates raised its stake in Mirum Pharmaceuticals by 57.1% during the 3rd quarter. Raymond James & Associates now owns 106,207 shares of the company's stock worth $3,356,000 after acquiring an additional 38,619 shares in the last quarter. Rafferty Asset Management LLC lifted its position in Mirum Pharmaceuticals by 18.4% in the third quarter. Rafferty Asset Management LLC now owns 137,205 shares of the company's stock valued at $4,336,000 after acquiring an additional 21,312 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Mirum Pharmaceuticals by 210.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 224,571 shares of the company's stock valued at $7,096,000 after acquiring an additional 152,287 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Mirum Pharmaceuticals by 202.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 114,109 shares of the company's stock worth $3,606,000 after purchasing an additional 76,369 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.